Meta-Analysis of 38 Studies Reveals Potential of Ivermectin as Adjuvant Therapy for Mild-to-Moderate COVID-19 Patients & Reduced Risk of Mortality

Meta-Analysis of 38 Studies Reveals Potential of Ivermectin as Adjuvant Therapy for Mild-to-Moderate COVID-19 Patients & a Reduced Risk of Mortality

A group of researchers from prominent institutions, including Mayo Clinic, Rochester and Government Medical College in India, recently conducted a comprehensive meta-analysis evaluating the benefits and possible risks associated with the use of ivermectin as a treatment option targeting SARS-CoV-2, the virus behind COVID-19. The authors recently shared the results with medRxiv. Although not peer reviewed nor published as of yet, the findings were of interest and are now available on the preprint server medRxiv. Their efforts are premised on the challenge that despite over a year of intensive R&D spend in the billions of dollars, there is still no effective therapy for the COVID-19 virus. The authors acknowledge that ivermectin has demonstrated positive results in several observational studies and after a review of 38 studies covering 15,002 patients, the research team came to the conclusion that their analysis points to ivermectin as a possibly effective adjuvant therapy in helping to reduce mortality—only in those patients with mild-to-moderate clinical presentation of COVID-19 based on high certainty of evidence from RCTs subgroup analysis. However, certainty of evidence was...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee